Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$29.43 USD
+0.40 (1.38%)
Updated Apr 18, 2024 03:59 PM ET
After-Market: $29.45 +0.02 (0.07%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Average Brokerage Rating
Current ABR | 1.78 |
ABR (Last week) | 1.78 |
# of Recs in ABR | 9 |
Average Target Price | $41.17 |
LT Growth Rate | 22.80% |
Industry | Medical - Products |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -1.63 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.78 | 1.78 | 1.78 | 1.78 | 1.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
11/2/2023 | Not Identified | Not Identified | Hold | Hold |
10/25/2023 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.